CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The LapIt project seeks to develop a targeted treatment for Acute Myeloid Leukemia (AML) using an antibody-drug conjugate designed to specifically attack cancer cells. This approach aims to improve treatment efficacy and tolerability for all AML patients.
Acute Myeloid Leukemia (AML), a cancer of the myeloid line of blood cells, is the most common type of leukemia in adults (~350.000 new cases yearly worldwide), yet continues to have the lowest overall survival rate of all leukemias (26.9%).
The disease is characterized by clonal expansion of undifferentiated myeloid precursors, leading to anomalous hematopoiesis and bone marrow failure.
Current AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell t…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
